Cohance Lifesciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+89.5%+19.2%
EBITDA+13.8%−9.0%
Net Income−43.3%−28.5%
EPS (adj.)−33.1%−24.2%
Total Assets+89.1%+42.8%
Total Equity+119.3%+32.5%
Free Cash Flow+12.1%−3.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

COHANCE₹452.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹17,294 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+89.5+19.2
EBITDA+13.8-9.0
Net Income-43.3-28.5
EPS (adj.)-33.1-24.2
Total Assets+89.1+42.8
Total Equity+119.3+32.5
Free Cash Flow+12.1-3.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.